PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Scientific advice
Prevention and control of communicable diseases in prison settings.
Shoman et al. Globalization and Health (2017) 13:1 DOI 10.1186/s12992-016-0224-2
DHS Working Papers No. 98.
A new report by the world’s largest humanitarian network warns that the number of people needing humanitarian assistance every year as a result of climate-related disasters could double by 2050. It estimates that the number of people in need of humanitarian assistance as a result of storms, droug...hts and floods could climb beyond 200 million annually – compared to an estimated 108 million today.
It further suggests that this rising human toll would come with a huge financial price tag, with climate-related humanitarian costs ballooning
more
A toolkit for Implementation. Module 3: Participatory community assessment in maternal and newborn health
A Toolkit for Implementation. Module 5: Finalizing, monitoring and evaluating the IFC action plan
A Toolkit for Implementation. Module 2: Facilitator’s guide to the orientation workshop on the IFC framework;
Johnson CC et al. Journal of the International AIDS Society 2017, 20:21594 http://www.jiasociety.org/index.php/jias/article/view/21594 | https://doi.org/10.7448/IAS.20.1.21594
The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit...h DM have a worse prognosis than those without DM. Diabetes can cause myocardial ischemia via micro- and macrovasculopathy and can directly exert deleterious effects on the myocardium. Hyperglycemia, hyperinsulinemia, and insulin resistance can cause alterations in vascular homeostasis. Then, reduced nitric oxide and increased reactive oxygen species levels favor inflammation leading to atherothrombotic progression and myocardial dysfunction. The classification, diagnosis, and treatment of HF for a patient with and without DM remain the same. Until now, drugs targeting neurohumoral and metabolic pathways improved mortality and morbidity in HF with reduced ejection fraction (HFrEF). Therefore, all HFrEF patients should receive guideline-directed medical therapy. By contrast, drugs modulating neurohumoral activity did not improve survival in HF with preserved ejection fraction (HFpEF) patients. Trials investigating whether sodium-glucose cotransporter-2 inhibitors are effective in HFpEF are on-going. This review will summarize the epidemiology, pathophysiology, and treatment of HF in diabetes.
more